SELLAS Life Sciences (SLS) Times Interest Earned (2011 - 2026)
SELLAS Life Sciences' (SLS) quarterly Times Interest Earned came in at -$1.59 in Q1 2026, up 94.74% year-on-year from -$0.82 in Q1 2025, and up 98.07% on a QoQ basis from -$82.55 in Q4 2025.
SELLAS Life Sciences (SLS) Times Interest Earned (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 14 years of Times Interest Earned data on file, last reported at -$1.59 in Q1 2026.
- On a quarterly basis, Times Interest Earned rose 94.74% year-over-year to -$1.59 in Q1 2026; TTM through Mar 2026 was -$5.42, a 90.29% increase from a year earlier, with the FY2025 full-year figure at -$1.24, up 18.03% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$1.59, up from -$82.55 in the prior quarter.
- Over the last five years, Times Interest Earned for SLS reached as high as -$1.59 in Q1 2026 and fell as low as -$167.35 in Q1 2022.
- Historically, Times Interest Earned has averaged -$71.72 across 5 years, with a median of -$76.21 in 2024.
- Across the five-year window, Times Interest Earned sank 645.43% in 2022 and soared 95.61% in 2025, its largest moves.
- Year by year, Times Interest Earned stood at -$47.23 in 2022, then sank by 73.13% to -$81.77 in 2023, then advanced by 15.4% to -$69.18 in 2024, then slipped by 19.33% to -$82.55 in 2025, then jumped by 98.07% to -$1.59 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were -$1.59 in Q1 2026, -$82.55 in Q4 2025, and -$35.42 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -0.38 |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | -1.59 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.59 |
| Dec 31, 2025 | -82.55 |
| Sep 30, 2025 | -35.42 |
| Jun 30, 2025 | -3.34 |
| Mar 31, 2025 | -30.32 |
| Dec 31, 2024 | -69.18 |
| Sep 30, 2024 | -73.29 |
| Jun 30, 2024 | -76.21 |
| Mar 31, 2024 | -96.45 |
| Dec 31, 2023 | -81.77 |
| Sep 30, 2023 | -93.61 |
| Jun 30, 2023 | -90.50 |
| Mar 31, 2023 | -112.81 |
| Dec 31, 2022 | -47.23 |
| Sep 30, 2022 | -71.46 |
| Jun 30, 2022 | -86.23 |
| Mar 31, 2022 | -167.35 |
| Dec 31, 2021 | -116.19 |
| Sep 30, 2021 | -69.77 |
| Jun 30, 2021 | -44.53 |